Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134394 · ClinicalTrials.gov registry record · Phase 2
Etanercept With Tacrolimus for Psoriasis
A Phase 2 study of Psoriasis, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00134394 is a Phase 2 study of Psoriasis that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 20 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00134394, a Phase 2 study of Psoriasis, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.
Conditions Studied
Interventions
- DRUG Etanercept plus tacrolimus
Study Locations (1)
New Jersey
- UMDNJ Psoriasis Center of Excellence - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134394
The ClinicalTrials.gov registry entry for NCT00134394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Etanercept plus tacrolimus is the first listed.
NCT00134394 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00134394 about?
NCT00134394 is a clinical study titled "Etanercept With Tacrolimus for Psoriasis". The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.
What is the current status of trial NCT00134394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-02. Estimated completion is 2007-12.
What conditions does trial NCT00134394 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00134394?
The interventions under investigation include: Etanercept plus tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00134394?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134394 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
-
Randomized Study of PH-10 for Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.